Status:
COMPLETED
A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Fungal Infection
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.
Eligibility Criteria
Inclusion
- Japanese Patients In Whom A Causative Fungus Is Detected Before Treatment With The Study Drug Or Patients With Strongly Suspected Deep-Seated Fungal Infection Due To Candida species (Spp.) Or Aspergillus Spp.
Exclusion
- Patients With Mycoses Other Than Ones Due To Candida Spp. Or Aspergillus Spp.
- Patients Who Will Receive Other Systemic Antifungal Agents For The First Time In Screening Period.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT00717860
Start Date
August 1 2008
End Date
July 1 2010
Last Update
March 23 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.